Trial Profile
A Dose-ranging Study to Compare the Safety and Immunogenicity of a Candidate Human Deficiency Virus (HIV) Vaccine 732461, Adjuvanted or Not, Administered According to a 0, 1 Month Schedule to Healthy Adult HIV Seronegative Volunteers.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 25 Jul 2023
Price :
$35
*
At a glance
- Drugs GSK 732461 (Primary) ; AS01B; AS02
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GSK
- 18 Feb 2011 Primary endpoint 'CD4+-cell-count' has been met
- 08 Feb 2009 Results were presented at CROI 2009.
- 12 Oct 2008 Trial phase changed from I/II to II as reported by ClinicalTrials.gov.